Current regulatory issues in cell and tissue therapy

Area of Science:

• Regenerative Medicine
• Biotechnology
• Regulatory Science

Background:

• Cell-based therapies have advanced significantly, moving beyond transplantation to tissue repair, regeneration, and immune functions.
• The increasing complexity of human cells, tissues, and cellular and tissue-based products (HCT/Ps) introduces potential risks of adverse events.
• Regulatory bodies are implementing frameworks to manage these risks and ensure product safety.

Purpose of the Study:

• To outline the regulatory framework for human cells, tissues, and cellular and tissue-based products (HCT/Ps).
• To explain the roles of proposed Good Tissue Practices (GTP) and existing Good Manufacturing Practices (GMP) in ensuring product safety and efficacy.
• To highlight the tiered, risk-based approach to regulating HCT/Ps.

Main Methods:

• Implementation of a tiered, risk-based regulatory structure by the US Food and Drug Administration.
• Establishment of Good Tissue Practices (GTP) to prevent contamination and ensure product integrity.
• Application of Good Manufacturing Practices (GMP) for enhanced process control and product characterization for higher-risk products.

Main Results:

• All HCT/Ps must comply with GTPs.
• Higher-risk HCT/Ps require adherence to both GTPs and GMPs, including premarket approval via the Investigational New Drug (IND) mechanism.
• These regulations aim to increase safety, control, and data reliability in cell-based therapies.

Conclusions:

• The regulatory framework, including GTP and GMP, is essential for managing the risks associated with advanced cell-based therapies.
• Compliance with these regulations supports good clinical care and enables robust scientific advancement.
• The tiered approach ensures appropriate oversight based on the potential risk posed by different HCT/Ps.